Oncolytics Biotech (TSE:ONC) has released an update.
Oncolytics Biotech is advancing toward FDA accelerated approval with promising trial results for their breast and pancreatic cancer treatments, particularly highlighting the success of their pelareorep + paclitaxel therapy in the BRACELET-1 trial. The company is also preparing for significant clinical milestones in 2025, including a study that could cement pelareorep as a key therapeutic option for breast cancer patients resistant to current treatments.
For further insights into TSE:ONC stock, check out TipRanks’ Stock Analysis page.
